These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 33791194

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z, Cai Z, Cai Q, Hong Y, Zhang C, Huang K, Lin Z, Li M.
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [Abstract] [Full Text] [Related]

  • 3. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B, Hu Y, Xiong RH, Pan YF, Xu QL, Kong XY, Cai R, Chen QQ, Tang HY, Jiang W.
    Oncotarget; 2017 Feb 21; 8(8):14078-14088. PubMed ID: 27845907
    [Abstract] [Full Text] [Related]

  • 4. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ, Huang PY, Shi JL, Xia HQ, Zhao C, Cao KJ.
    Chin J Cancer; 2016 Jan 06; 35():2. PubMed ID: 26739148
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Qiu F, Sun R, Chen QY, Huang PY, Luo DH, Hua YJ, Wu YS, Lv X, Wang L, Xia WX, Tang LQ, Ye YF, Chen MY, Guo X, Hong MH.
    Eur J Cancer; 2017 Apr 06; 75():14-23. PubMed ID: 28214653
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R, Zhu J, Chen X, Liu Y, Wang Y, Zhang T.
    Clin Transl Oncol; 2020 Mar 06; 22(3):429-439. PubMed ID: 31165410
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial.
    Chitapanarux I, Kittichest R, Tungkasamit T, Asakit T, Chomprasert K, Chakrabandhu S, Onchan W, Traisathit P.
    Curr Probl Cancer; 2021 Feb 06; 45(1):100620. PubMed ID: 32713518
    [Abstract] [Full Text] [Related]

  • 11. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
    Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY.
    Eur J Cancer; 2019 Sep 06; 119():87-96. PubMed ID: 31425966
    [Abstract] [Full Text] [Related]

  • 12. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M, Yokota T, Hamauchi S, Onozawa Y, Ogawa H, Onoe T, Kamijo T, Iida Y, Nishimura T, Onitsuka T, Yasui H.
    Jpn J Clin Oncol; 2017 Aug 01; 47(8):705-712. PubMed ID: 28431119
    [Abstract] [Full Text] [Related]

  • 13. Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Tao HY, Zhan ZJ, Qiu WZ, Liao K, Yuan YW, Yuan TZ, Zheng RH.
    J Cancer; 2021 Aug 01; 12(1):18-27. PubMed ID: 33391399
    [Abstract] [Full Text] [Related]

  • 14. Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.
    Mané M, Benkhaled S, Dragan T, Paesmans M, Beauvois S, Lalami Y, Szturz P, Gaye PM, Vermorken JB, Van Gestel D.
    Oncologist; 2021 Jan 01; 26(1):e130-e141. PubMed ID: 32924198
    [Abstract] [Full Text] [Related]

  • 15. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C, Sun R, Tang LL, Chen L, Li WF, Mao YP, Zhou GQ, Guo R, Lin AH, Sun Y, Ma J, Hu WH.
    Oral Oncol; 2018 Mar 01; 78():37-45. PubMed ID: 29496056
    [Abstract] [Full Text] [Related]

  • 16. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma : A matched-pair multicenter analysis of outcomes.
    Dong YY, Xiang C, Lu JX, Su YX, Pan YF, Cai R, Zhang RJ, He ZK, Liu ML, Huang H, Bai X, Tang HY, Shi YH, Wang Y, Jiang W.
    Strahlenther Onkol; 2016 Jun 01; 192(6):394-402. PubMed ID: 27215563
    [Abstract] [Full Text] [Related]

  • 17. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J, Thephamongkhol K.
    BMC Cancer; 2018 Mar 27; 18(1):329. PubMed ID: 29587665
    [Abstract] [Full Text] [Related]

  • 18. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Lin M, You R, Liu YP, Zhang YN, Zhang HJ, Zou X, Yang Q, Li CF, Hua YJ, Yu T, Cao JY, Li JB, Mo HY, Guo L, Lin AH, Sun Y, Qian CN, Ma J, Mai HQ, Chen MY.
    Oral Oncol; 2018 May 27; 80():1-8. PubMed ID: 29706183
    [Abstract] [Full Text] [Related]

  • 19. The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study.
    Wang ZQ, Feng XD, Ge CL, Yang Y, Liang N, Ye Q, Fu Y, Wei J, Zhang Y, Li RQ.
    Radiat Oncol; 2022 Nov 17; 17(1):189. PubMed ID: 36397078
    [Abstract] [Full Text] [Related]

  • 20. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
    Liao K, Tao HY, Zhan ZJ, Qiu WZ, Zheng RH.
    Oncol Res Treat; 2021 Nov 17; 44(11):602-612. PubMed ID: 34601467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.